Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Other Operating Expenses (2022 - 2024)

Denali Therapeutics (DNLI) has disclosed Other Operating Expenses for 3 consecutive years, with $14.5 million as the latest value for Q1 2024.

  • On a quarterly basis, Other Operating Expenses changed N/A to $14.5 million in Q1 2024 year-over-year; TTM through Dec 2024 was $14.5 million, a N/A change, with the full-year FY2024 number at $14.5 million, changed N/A from a year prior.
  • Other Operating Expenses was $14.5 million for Q1 2024 at Denali Therapeutics, down from $92.1 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $92.1 million in Q4 2022 to a low of $14.5 million in Q1 2024.
  • A 3-year average of $63.7 million and a median of $65.7 million in 2021 define the central range for Other Operating Expenses.
  • Biggest YoY gain for Other Operating Expenses was 43.0% in 2022; the steepest drop was 43.0% in 2022.
  • Denali Therapeutics' Other Operating Expenses stood at $65.7 million in 2021, then soared by 40.18% to $92.1 million in 2022, then crashed by 84.22% to $14.5 million in 2024.
  • Per Business Quant, the three most recent readings for DNLI's Other Operating Expenses are $14.5 million (Q1 2024), $92.1 million (Q4 2022), and $86.1 million (Q1 2022).